MIM
TNXP icon

MetLife Investment Management’s Tonix Pharmaceuticals TNXP Stock Holding History

MetLife Investment Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$118K Buy
8,590
+3,975
+86% +$61.2K ﹤0.01% 2465
2025
Q4 		$72.1K Hold
4,615
– – ﹤0.01% 2691
2025
Q3 		$111K Hold
4,615
– – ﹤0.01% 2605
2025
Q2 		$166K Buy
+4,615
New +$121K ﹤0.01% 2282
2021
Q3 		– Hold
0
– -$150K – 2583
2021
Q2 		– Hold
0
– – – 2325

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

MetLife Investment Management's TNXP Position: Q1 2026 in Review

MetLife Investment Management increased its Tonix Pharmaceuticals (TNXP) stake by 86% in Q1 2026, buying an estimated $61.2K and bringing the position to 8,590 shares worth $118K. The position accounts for ﹤0.01% of the portfolio, ranked #2465.

MetLife Investment Management first reported a position in TNXP in Q2 2025 and has held it in 4 quarters since. The position peaked at $166K in Q2 2025. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • MetLife Investment Management held 8,590 shares of Tonix Pharmaceuticals worth $118K as of Q1 2026.
  • MetLife Investment Management bought 3,975 Tonix Pharmaceuticals shares in Q1 2026, an estimated $61.2K.
  • Tonix Pharmaceuticals made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2465 holding.
  • MetLife Investment Management first reported a position in Tonix Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • MetLife Investment Management's Tonix Pharmaceuticals position peaked at $166K in Q2 2025.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.